UNSPSC 51343818: Nevirapine and lamivudine/tenofovir DF

This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.

UNSPSC 51343818 Nevirapine and lamivudine/tenofovir DF is a Commodity code that describes antiretroviral medications used to treat HIV infection. The code shows no current state and local procurement activity directly aligned with its pharmaceutical scope. Of the recent opportunities posted under this code, none involve the purchase of nevirapine, lamivudine, or tenofovir DF medications themselves. Instead, the tagged opportunities span unrelated categories: a mobile emergency-medical-services application for drug-dosage calculation (Collier County), a general pharmaceutical services contract for a long-term-care facility (Dane County), a trade show and conference calendar (Clay County and Marion County), an aquatic center operational partnership (Palm Bay), and forensic drug reference standards for law enforcement analysis (Pinellas County). Only the Dane County and West Texas Centers opportunities represent traditional pharmaceutical contracting, and neither involves antiretroviral drugs or HIV treatment protocols.

The geographic spread of the mistagged opportunities spans Florida (Collier, Dane, Palm Bay, Seminole, Marion Counties), Wisconsin (Dane County), Oregon (Washington County), Kentucky (Owensboro), California (San Mateo County), Arizona (Tucson), Texas (West Texas Centers, Williamson County), and the District of Columbia, reflecting a broad but unfocused activity pattern. The source contains no evidence of active state and local procurement for antiretroviral medications, no issuing-body repeat buyers for this therapeutic category, and no representative recent solicitations tied to HIV treatment supply chains. Opportunities involving naloxone distribution (Washington County, Oregon; Seminole County, Florida) and opioid use disorder treatment grants (Bernalillo County) address substance-use disorders rather than HIV care. The code appears dormant for state and local contracting purposes based on available recent records.